TP53 and lung cancer: However, due to the high prevalence of TP53 driven clones in those at higher risk for lung cancer, there is greater risk that with reduced immune surveillance in advanced age and perhaps due to a regional sub-optimal immune surveillance deficit, a clone will escape detection, acquire additional driver mutations, and begin to invade.